Business Wire

VA-CTA

3.10.2018 22:02:11 CEST | Business Wire | Press release

Share
CES Unveiled Paris Shines a Spotlight on Tech Innovation

The Consumer Technology Association (CTA)TM hosted the sixth annual CES Unveiled Paris today, making several announcements and shining a spotlight on the latest tech innovation. Co-located for the first time with the Mondial Paris Motor Show , CES Unveiled Paris gathered innovative exhibitors, media and industry professionals to experience the latest tech trends and products expected at CES® 2019 that will change our world for the better. Owned and produced by CTA, CES 2019 will run January 8-11, 2019 in Las Vegas, Nevada.

During the event, CTA Executive Vice President of CES Karen Chupka announced 55 French companies selected as CES® 2019 Innovation Honorees . Selected Honorees included GEOFLEX in the vehicle intelligence and self-driving category and Pixminds honored in the gaming category.

“CES Unveiled Paris highlights the innovative spirit fueling Europe’s dynamic tech market, and the French companies recognized as this year’s CES Innovation Award honorees represent the future of technology,” said Chupka. “The products and services honored today reflect the ingenuity driving our industry forward and improving the way we live, work and play.”

The remaining Innovation honorees will be announced at CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.

CTA President and CEO Gary Shapiro also announced today that Dr. Lisa Su, president and CEO of AMD, will deliver a keynote at CES 2019. Dr. Su joins IBM CEO Ginni Rometty as confirmed CES 2019 keynote speakers, with additional speakers to be announced in the coming weeks.

Showcasing the latest technology products and celebrating European innovation, CES Unveiled Paris was the largest event since its inaugural debut in 2013. The event hosted 1,051 attendees from 44 countries and regions, and featured more than 76 exhibitors.

Now a full-day event, and in collaboration with the Connecting Leaders Club, CES Unveiled Paris debuted the Executive Forum on Innovation, with programming focused on emerging trends including mobility, energy and environment and artificial intelligence. More than 20 speakers were featured, including executives from Axa, Accenture, Google, Salesforce and Valeo, as they discussed the future of innovation, including trends expected at CES this January.

CES 2019 is the world’s most important and influential event. The 2019 event will showcase life-changing technology across every major industry, featuring 4,500 exhibitors across 2.75M net square feet (260K net square meters) of exhibit space. CES provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more.

CES is also one of the largest displays of vehicle technology in the world and was recently named as USA Today’s 10 Best Auto Shows. The 2019 show will feature more than 150 vehicle tech companies, including eight automakers, featuring the latest concept cars and connected vehicles.

Areas new to CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.

Registration for CES 2019 is now open. For the latest exhibitor news and show announcements, visit CES.tech .

High-definition video b-roll of CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .

About CES:

CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .

About Consumer Technology Association:

Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.

UPCOMING EVENTS

Contact:

Consumer Technology Association Teresa Hsu, 703-907-5259 thsu@CTA.tech www.CES.tech or Justin Siraj, 703-907-7415 jsiraj@CTA.tech www.CES.tech

Link:

ClickThru

Social Media:

https://www.facebook.com/CES

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye